Which 5HT receptor agonist is used for chronic anxiety while having little to no potential for abuse?

The choice of Buspirone (Buspar) as a 5HT receptor agonist for chronic anxiety is grounded in its unique pharmacological profile. Buspirone primarily acts as a partial agonist at the serotonin 5HT1A receptors, which plays a significant role in the modulation of mood and anxiety. Its mechanism helps to increase serotonin activity in the brain, contributing to its anxiolytic effects.

One of the distinguishing features of Buspirone is its low potential for abuse. Unlike many other anxiolytic medications, such as benzodiazepines or certain sedatives, Buspirone does not produce significant sedative effects or euphoria that commonly lead to misuse or dependency. This characteristic makes it particularly suitable for long-term management of anxiety disorders, especially in patients who may be concerned about the addictive potential of alternative treatments.

In contrast, the other options listed—Zolpidem, Hydroxyzine, and Temazepam—are associated with higher abuse potential due to their sedative effects and mechanisms that can lead to physical dependence or a feeling of intoxication. Therefore, Buspirone stands out not only for its effectiveness in treating chronic anxiety but also for providing a safer alternative with minimal risk of dependency.